NCT07222215
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07222215
Title PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) (CAPELA)
Acronym CAPELA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kristina A. Fanucci
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field